$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168316822008081 Filed on November 29, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$5.253M	$4.258M	$4.602M
YoY Change	-3.56%	-7.49%	506.06%
Cost Of Revenue	$2.955M	$2.356M	$1.204M
YoY Change	43.71%	95.65%	415.93%
Gross Profit	$2.298M	$1.901M	$3.398M
YoY Change	-32.23%	-44.04%	546.06%
Gross Profit Margin	43.75%	44.66%	73.83%
Selling, General & Admin	$7.080M	$4.858M	$4.208M
YoY Change	36.63%	15.44%	221.83%
% of Gross Profit	308.1%	255.47%	123.84%
Research & Development	$0.00	$0.00	$60.17K
YoY Change		-100.0%	163.67%
% of Gross Profit	0.0%	0.0%	1.77%
Depreciation & Amortization	$127.8K	$43.66K	$41.64K
YoY Change	142.84%	4.85%	291.35%
% of Gross Profit	5.56%	2.3%	1.23%
Operating Expenses	$7.080M	$4.858M	$4.310M
YoY Change	35.26%	12.71%	223.96%
Operating Profit	-$4.782M	-$2.956M	-$911.9K
YoY Change	159.4%	224.19%	13.36%
Interest Expense	$1.221M	$672.1K	-$79.52K
YoY Change	-648.27%	-945.23%	-43.65%
% of Operating Profit
Other Income/Expense, Net	$299.9K	-$214.0K	$14.71K
YoY Change	-20642.74%	-1554.78%	-59.33%
Pretax Income	-$4.482M	-$3.170M	-$976.7K
YoY Change	116.78%	224.59%	7.4%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.413M	-$3.618M	-$2.266M
YoY Change	30.36%	59.67%	147.81%
Net Earnings / Revenue	-84.01%	-84.97%	-49.23%
Basic Earnings Per Share	-$0.05	-$0.05	-$0.03
Diluted Earnings Per Share	-$0.05	-$0.05	-$30.64K
COMMON SHARES
Basic Shares Outstanding	85.20M shares	79.99M shares	73.96M shares
Diluted Shares Outstanding	84.44M shares	72.22M shares	73.96M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.110M	$936.3K	$92.34K
YoY Change	514.09%	913.92%	-33.76%
Cash & Equivalents	$1.110M	$936.3K	$92.34K
Short-Term Investments
Other Short-Term Assets	$627.6K	$1.178M	$311.5K
YoY Change	146.33%	278.09%	141.43%
Inventory	$2.510M	$1.647M	$1.113M
Prepaid Expenses
Receivables	$5.492M	$5.979M	$4.310M
Other Receivables	$507.4K	$552.3K	$61.78K
Total Short-Term Assets	$10.34M	$10.43M	$5.888M
YoY Change	27.35%	77.21%	328.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.528M	$1.374M	$1.280M
YoY Change	-14.7%	7.37%	-5.28%
Goodwill	$4.253M	$4.253M
YoY Change
Intangibles	$3.740M	$3.530M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.72M	$14.56M	$2.759M
YoY Change	343.33%	427.9%	80.95%
TOTAL ASSETS
Total Short-Term Assets	$10.34M	$10.43M	$5.888M
Total Long-Term Assets	$14.72M	$14.56M	$2.759M
Total Assets	$25.06M	$25.00M	$8.646M
YoY Change	119.07%	189.09%	198.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.552M	$2.095M	$711.2K
YoY Change	96.96%	194.65%	375.27%
Accrued Expenses	$3.477M	$3.128M	$3.359M
YoY Change	-5.32%	-6.87%	-69.93%
Deferred Revenue	$1.530M	$696.2K
YoY Change
Short-Term Debt	$17.17M	$13.17M	$404.9K
YoY Change	284.63%	3152.86%	-92.68%
Long-Term Debt Due	$687.2K	$622.8K
YoY Change
Total Short-Term Liabilities	$27.31M	$23.90M	$5.460M
YoY Change	155.55%	337.79%	-69.85%
LONG-TERM LIABILITIES
Long-Term Debt	$9.445M	$9.755M	$9.879M
YoY Change	-4.41%	-1.25%
Other Long-Term Liabilities	$7.815M	$7.646M	$287.8K
YoY Change	1036.42%	2556.54%	-65.1%
Total Long-Term Liabilities	$17.26M	$17.40M	$10.17M
YoY Change	63.32%	71.16%	1132.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.31M	$23.90M	$5.460M
Total Long-Term Liabilities	$17.26M	$17.40M	$10.17M
Total Liabilities	$44.57M	$41.30M	$16.99M
YoY Change	102.04%	143.13%	-10.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.5M	-$125.1M
YoY Change
Common Stock	$428.3K	$401.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$20.37M	-$17.23M	-$8.342M
YoY Change
Total Liabilities & Shareholders Equity	$25.06M	$25.00M	$8.646M
YoY Change	119.07%	189.09%	198.38%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.413M	-$3.618M	-$2.266M
YoY Change	30.36%	59.67%	147.81%
Depreciation, Depletion And Amortization	$127.8K	$43.66K	$41.64K
YoY Change	142.84%	4.85%	291.35%
Cash From Operating Activities	-$3.704M	-$1.208M	-$3.213M
YoY Change	144.28%	-62.41%	716.84%
INVESTING ACTIVITIES
Capital Expenditures	$561.8K	$341.5K	-$217.9K
YoY Change	-568.69%	-256.76%	219.93%
Acquisitions
YoY Change
Other Investing Activities	$70.98K
YoY Change
Cash From Investing Activities	-$490.8K	-$429.5K	-$217.9K
YoY Change	309.47%	97.15%	219.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$14.83K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.925M	$2.642M	3.373M
YoY Change	127.66%	-21.69%	559.45%
NET CHANGE
Cash From Operating Activities	-3.704M	-$1.208M	-3.213M
Cash From Investing Activities	-490.8K	-$429.5K	-217.9K
Cash From Financing Activities	3.925M	$2.642M	3.373M
Net Change In Cash	-269.3K	$1.005M	-57.29K
YoY Change	-405.71%	-1853.48%	-214.31%
FREE CASH FLOW
Cash From Operating Activities	-$3.704M	-$1.208M	-$3.213M
Capital Expenditures	$561.8K	$341.5K	-$217.9K
Free Cash Flow	-$4.265M	-$1.549M	-$2.995M
YoY Change	205.48%	-48.27%	820.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	000-12641
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
CY2022Q3	dei	City Area Code CityAreaCode	858
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	283-1253
CY2022Q3	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
CY2022Q3	dei	Trading Symbol TradingSymbol	DFCO
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85199144	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	936253	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	904141	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5978764	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6406555	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	141554	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	41603	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	552301	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	288655	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1647321	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	273763	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430070	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	10434097	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9563566	usd
CY2022Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41777	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2022Q3	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1200496	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374291	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2022Q3	us-gaap	Goodwill Goodwill	4253424	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3529794	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3524888	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1552662	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1665436	usd
CY2022Q3	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	2609731	usd
CY2022Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	1087256	usd
CY2022Q3	us-gaap	Assets Assets	24996272	usd
CY2022Q2	us-gaap	Assets Assets	22422480	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2095488	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2331919	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3128206	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1799404	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2037712	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1275982	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1270133	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	696223	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	720923	usd
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	622789	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	669028	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	12542744	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9269377	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	628392	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1495528	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	388071	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	435647	usd
CY2022Q3	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	487490	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	369050	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	23903097	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20416745	usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	82839	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	120534	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9193341	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9538685	usd
CY2022Q3	DFCO	Contingent Consideration ContingentConsideration	4356467	usd
CY2022Q2	DFCO	Contingent Consideration ContingentConsideration	4870800	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1167617	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231691	usd
CY2022Q3	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	2122242	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	718206	usd
CY2022Q3	us-gaap	Liabilities Liabilities	41304604	usd
CY2022Q2	us-gaap	Liabilities Liabilities	37375662	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80320974	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80320974	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72174620	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72174620	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	401587	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	360855	usd
CY2022Q3	DFCO	Common Stock To Be Issued CommonStockToBeIssued	716925	usd
CY2022Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	1066925	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106687564	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104627032	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	926632	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	479019	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125054279	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121436490	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13089	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50673	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16308332	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24996272	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22422480	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4172249	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4587044	usd
CY2022Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	85518	usd
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	15309	usd
CY2022Q3	us-gaap	Revenues Revenues	4257767	usd
CY2021Q3	us-gaap	Revenues Revenues	4602353	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2356328	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1204335	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1901439	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	3398018	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	467517	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	677507	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4857617	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4249699	usd
CY2022Q3	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	0	usd
CY2021Q3	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	60174	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4857617	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	4309873	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2956178	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-911855	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	672127	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	123804	usd
CY2022Q3	us-gaap	Interest Income Operating InterestIncomeOperating	19069	usd
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	527	usd
CY2022Q3	us-gaap	Other Income OtherIncome	338077	usd
CY2021Q3	us-gaap	Other Income OtherIncome	14708	usd
CY2022Q3	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	53266	usd
CY2021Q3	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	47717	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	43751	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-213998	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-64818	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3170176	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-976673	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3170176	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-976673	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	447613	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1289169	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3617789	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2265842	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	63762	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	39344	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3106414	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-937329	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72217851	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73955420	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72217851	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73955420	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13407388	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6532206	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1	usd
CY2021Q3	DFCO	Joint Venture JointVenture	169745	usd
CY2021Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	14826	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	677507	usd
CY2021Q3	DFCO	Profit Loss1 ProfitLoss1	-976673	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39344	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6980084	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022Q3	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium	1111397	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172350	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	467517	usd
CY2022Q3	DFCO	Profit Loss1 ProfitLoss1	-3170176	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	63762	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16308332	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3170176	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-976673	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	126753	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41637	usd
CY2022Q3	DFCO	Share Based Compensation1 ShareBasedCompensation1	467517	usd
CY2021Q3	DFCO	Share Based Compensation1 ShareBasedCompensation1	677507	usd
CY2022Q3	DFCO	Bad Debt Expense BadDebtExpense	49659	usd
CY2021Q3	DFCO	Bad Debt Expense BadDebtExpense	0	usd
CY2022Q3	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-341983	usd
CY2021Q3	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	452865	usd
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022Q3	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	53266	usd
CY2021Q3	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	-0	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-278181	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3973740	usd
CY2022Q3	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	263646	usd
CY2021Q3	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5557	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22700	usd
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	270687	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-156307	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	26515	usd
CY2022Q3	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-9225	usd
CY2021Q3	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-0	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-236432	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-140754	usd
CY2022Q3	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-37695	usd
CY2021Q3	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	0	usd
CY2022Q3	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	5849	usd
CY2021Q3	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	500597	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1360199	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	711573	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	35242	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	23690	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-24700	usd
CY2021Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	249526	usd
CY2022Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-1125	usd
CY2021Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	34438	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1207676	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3212720	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	341538	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	122871	usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	88000	usd
CY2021Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	95000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-429538	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-217871	usd
CY2022Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3680279	usd
CY2021Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3399035	usd
CY2022Q3	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	752256	usd
CY2021Q3	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2022Q3	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-46239	usd
CY2021Q3	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-10911	usd
CY2022Q3	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	240000	usd
CY2021Q3	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
CY2022Q3	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	-0	usd
CY2021Q3	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	14826	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2641784	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3373298	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1004570	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57293	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63762	usd
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39344	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110285	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1840394	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92336	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	29766	usd
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q3	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	0	usd
CY2021Q3	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	6532206	usd
CY2022Q3	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	0	usd
CY2021Q3	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2022Q3	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	0	usd
CY2021Q3	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	58560	usd
CY2022Q3	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	1111397	usd
CY2021Q3	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	0	usd
CY2022Q3	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	1318284	usd
CY2021Q3	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	0	usd
CY2022Q3	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zsgbxFghSsZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_z7vAEr6Pb8Gd">Organization and Nature of Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Moving the world forward takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada accelerates positive change for current and future generations by harnessing true potential and developing products and services that become transformative innovations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Since Dalrada’s inception, the Company has grown its footprint to include the unique business divisions: <b>Dalrada Health</b>, <b>Dalrada Energy Services</b>, <b>Dalrada Precision Manufacturing</b>, and <b>Dalrada Technologies</b>. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Health</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Dalrada Health delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Dalrada Health delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Empower Genomics (“Empower”)</b>- Empower is Dalrada’s wholly owned diagnostic laboratory which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pala Diagnostics (“Pala”)</b>- Pala is a joint venture diagnostic laboratory which processes both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Solas Corp. (“Solas”)</b>- Solas manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>International Health Group (“IHG”)</b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pacific Stem Cells (“PSC”)</b>- PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products (HCT/Ps).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Watson Rx Solutions (“Watson”)</b>- In June 2022, Dalrada Health acquired Watson, an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Watson specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Watson maintains pharmacy licenses in all 50 States including Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>GlanHealth (“GlanHealth”)</b>- Dalrada Health Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands, and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors, vendors, and formulators for the development, sale, and marketing of its products and services</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Energy Services</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dalrada Energy Services (‘DES’) employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint. Through innovative products and commercial services, DES facilitates energy transition for universities, businesses, government buildings, and more. Reducing the world’s carbon footprint and achieving international Net Zero goals are no easy task. Fortunately, Dalrada Energy Services knows how and where to start. By providing robust commercial services that help organizations meet or exceed environmental standards, DES helps mitigate negative impacts for real-world energy transition saving clients up to 70% on energy while removing cost barriers for clients through innovative financing and savings share models.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Energy Services (“DES”)</b>- DES currently operates as a single subsidiary which provides end-to-end comprehensive energy service solutions in a robust commercial capacity, DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Precision Parts (“Precision”)</b>- Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Likido Ltd. (“Likido”)</b>- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">During the year, the U.S. Government selected Dalrada’s Likido®ONE high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The expected positive results should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial building industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Ignite I.T. (“Ignite”)</b>- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meet or exceed the most stringent industry-testing specifications. Ignites products are effective and available solutions to the increased demand for protecting employees from hazardous chemicals currently used and highlighted in recent federal and state regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Deposition Technologies (“DepTec”)</b>- Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">DepTec has built an impressive catalogue of precision OEM parts for PVD (<span style="background-color: white">Physical vapor deposition)</span> systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades –but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs and expect to meet the increased US market demand driven by the CHIPS and Science Act of 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Prakat (“Prakat”)</b>- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white">These condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2022, the Company has an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220930_zXdYmh0FKbjf" title="Accumulated deficit">125,054,279</span>. The Company closed a convertible debenture funding on February 4, 2022 for a total principal amount of $<span id="xdx_90B_ecustom--ConvertibleDebentureFunding_c20220204_pp0p0" title="Principal amount">3,000,000</span>. The continuation of the Company as a going concern is dependent upon the continued financial support from related parties, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125054279	usd
CY2022Q1	DFCO	Convertible Debenture Funding ConvertibleDebentureFunding	3000000	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	505270	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	18808062	usd
CY2022Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zVnNFWZmwR8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zuHVU2mrXXlg">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of inventory, valuation of accrued payroll tax liabilities, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, and deferred income tax asset valuation allowances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p>
CY2022Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z8Y1hUODKlPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zc5LBLLqz1q3">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Historical collection factors we considered for assessing collectability and determining net revenues and accounts receivable from our customers include the period of time that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">During the three months ended September 30, 2022, healthcare insurers and government payers accounted for over <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zqMy9zG8xrwc" title="Concentrations of credit risk">38</span>% of total revenues. Also, healthcare insurers and government payers amounted to total revenue of $<span id="xdx_90B_eus-gaap--Revenues_c20220701__20220930__srt--ProductOrServiceAxis__custom--HealthcareInsurersMember_pp0p0" title="Revenues">1,620,281</span>. The accounts receivable related to both healthcare insurers and government payers is $ <span id="xdx_906_eus-gaap--AccountsReceivableNet_c20220930__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_pp0p0" title="Accounts Receivable, after Allowance for Credit Loss">3,124,432</span> as of September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">As of September 30, 2022, and June 30, 2022, $<span id="xdx_90B_eus-gaap--ContractWithCustomerAssetSale_c20220701__20220930_zhHhX72idyK8" title="Sale from customer">705,500</span> and $<span id="xdx_90A_eus-gaap--ContractWithCustomerAssetSale_c20210701__20220630_zNphboUBhkyf" title="Sale from customer">880,500</span> is owed by a customer from the sale of several Likido units, respectively.</p>
CY2022Q3	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	705500	usd
CY2022	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	880500	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	467517	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	166901	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	119791	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2356328	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	677507	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	362855	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	12542744	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9193341	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	21736085	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9269377	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4257767	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4602353	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	5978764	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	6406555	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	141554	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	41603	usd
CY2022Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41777	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2022Q3	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1200496	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	696223	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	720923	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1204335	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-145777	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3524888	usd
CY2022Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	83093	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	109000	usd
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	93000	usd
CY2021Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1976714	usd
CY2022Q3	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	-514333	usd
CY2022Q3	DFCO	Contingent Consideration ContingentConsideration	4356467	usd
CY2021Q3	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2021Q4	us-gaap	Due From Joint Ventures DueFromJointVentures	2104509	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-28891	usd
CY2022	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	-116886	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	425107	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	399706	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1222214	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1224915	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1647321	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2022Q3	DFCO	Accrued Interest Rate AccruedInterestRate	Accrued interest is compounded daily at an estimated effective interest rate of 7.33%
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2037712	usd
CY2022Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	35242	usd
CY2021Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	23690	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	21736085	usd
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1080935	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	740147	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	440160	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	314642	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	369731	usd
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	518017	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1890826	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572806	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	516535	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	496394	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374291	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43659	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23532	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2022Q3	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	87999	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3758664	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-145777	usd
CY2022Q3	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	-83093	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-228870	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3529794	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	693385	usd
CY2022	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	2977280	usd
CY2021Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	18105	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2037712	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9538685	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	18808062	usd
CY2022Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	3320	usd
CY2022Q3	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	466460	usd
CY2022Q3	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	interest rate of Prime + 1%
CY2022Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2021-05-05
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	600000	usd
CY2022Q3	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	40000	usd
CY2022Q3	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	140000	usd
CY2022Q3	DFCO	Interest Accretion InterestAccretion	180000	usd
CY2022Q3	DFCO	Debenture In Cash DebentureInCash	200000	usd
CY2022Q3	DFCO	Debenture In Stock DebentureInStock	900000	usd
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	6813021	shares
CY2022Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	85518	usd
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	15309	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.44
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14225004	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.45
CY2022Q3	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	Each share of Series G Convertible Preferred share converts into 2,177 shares of common stock (equivalent to converting the related equity dollars into common shares at $0.30 per share).
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	250000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11025004	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025004	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2200000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9880982	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.45
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	467517	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	677507	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1439358	usd
CY2022Q3	us-gaap	Revenues Revenues	4257767	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2956178	usd
CY2021Q3	us-gaap	Revenues Revenues	4602353	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-911855	usd
CY2022Q3	us-gaap	Revenues Revenues	4257767	usd
CY2021Q3	us-gaap	Revenues Revenues	4602353	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1647321	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374291	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2405540	usd
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2405540	usd
CY2020Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.030	pure
CY2020Q2	DFCO	Imputed Interest ImputedInterest	192521	usd
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	140569	usd
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140569	usd
CY2020Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.030	pure

Files In Submission

Name	View Source	Status
0001683168-22-008081-index-headers.html	Edgar Link	pending
0001683168-22-008081-index.html	Edgar Link	pending
0001683168-22-008081.txt	Edgar Link	pending
0001683168-22-008081-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3102.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_ex3202.htm	Edgar Link	pending
dalrada_i10q-093022.htm	Edgar Link	pending
dfco-20220930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
dfco-20220930_cal.xml	Edgar Link	unprocessable
dfco-20220930_lab.xml	Edgar Link	unprocessable
dfco-20220930_def.xml	Edgar Link	unprocessable
dfco-20220930_pre.xml	Edgar Link	unprocessable
dalrada_i10q-093022_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2022 Q4 Form 10-Q Financial Statement

#000168316822008081 Filed on November 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2022 Q4 Form 10-Q Financial Statement

#000168316822008081 Filed on November 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco